Citation Impact
Citing Papers
Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
2009
PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib
2007
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
2007 StandoutScience
PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis
2011
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
2004 StandoutScience
First-Line Gefitinib for Patients With Advanced Non–Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Without Indication for Chemotherapy
2009
Autocrine Production of Amphiregulin Predicts Sensitivity to Both Gefitinib and Cetuximab in EGFR Wild-type Cancers
2008
Emergence of Epidermal Growth Factor Receptor T790M Mutation during Chronic Exposure to Gefitinib in a Non–Small Cell Lung Cancer Cell Line
2007
EGFR Antagonists in Cancer Treatment
2008 Standout
A phase II study of single-agent gefitinib as first-line therapy in patients with stage IV non-small-cell lung cancer
2006
Treatment of Medulloblastoma with Hedgehog Pathway Inhibitor GDC-0449
2009 Standout
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
2008 Standout
MYC on the Path to Cancer
2012 Standout
A view on drug resistance in cancer
2019 StandoutNature
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
2015 Standout
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
2009 StandoutNature
Comparing antibody and small-molecule therapies for cancer
2006
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
2009 Standout
Cell Signaling by Receptor Tyrosine Kinases
2010 Standout
Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer
2003 Standout
The biology and management of non-small cell lung cancer
2018 StandoutNature
First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
2014 Standout
Epidermal growth factor receptor mutations in lung cancer
2007 Standout
Serum biomarkers in idiopathic pulmonary fibrosis
2010
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2016 Standout
Lung Cancer
2008 Standout
Head and neck cancer
2008 Standout
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
2016 Standout
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
2004 Standout
Crizotinib inALK-Rearranged Inflammatory Myofibroblastic Tumor
2010 Standout
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
2010 StandoutNature
Genetics of fibrosing lung diseases
2005
Sarcoidosis
2013 Standout
Lung cancer: current therapies and new targeted treatments
2016 Standout
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
2005 Standout
Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa®, ZD1839) in chemotherapy‐resistant non‐small cell lung cancer
2004
ErbBs in lung cancer
2008
A review of the benefit–risk profile of gefitinib in Asian patients with advanced non‐small‐cell lung cancer
2006
Factors underlying sensitivity of cancers to small-molecule kinase inhibitors
2009
The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer
2005
EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer
2006
Detection of Mutations in EGFR in Circulating Lung-Cancer Cells
2008
Oncogenic Mutations Counteract Intrinsic Disorder in the EGFR Kinase and Promote Receptor Dimerization
2012 StandoutNobel
Targeting epidermal growth factor receptor—are we missing the mark?
2003
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
2016 Standout
Therapies Directed Against Epidermal Growth Factor Receptor in Aerodigestive Carcinomas
2007
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
2005 Standout
Pulmonary Microcirculation in Interstitial Lung Disease
2011
Understanding resistance to EGFR inhibitors—impact on future treatment strategies
2010
Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403)
2008
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
2005 Standout
Idiopathic pulmonary fibrosis
2011 Standout
The PI3K Pathway in Human Disease
2017 Standout
Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome
2005 Standout
Gefitinib for non-small-cell lung cancer treatment
2011
Rheumatologic Manifestations of Sarcoidosis
2010
Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology
2013
Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin–paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)
2012
Morphomolecular motifs of pulmonary neoangiogenesis in interstitial lung diseases
2019
Tyrosine kinase inhibitor resistance in cancer: role of ABC multidrug transporters
2005
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
2004 Standout
AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
2015 Standout
Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases
2019
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
2016 Standout
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
2009 Standout
Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis
2015
Pigment Epithelium–derived Factor in Idiopathic Pulmonary Fibrosis
2004
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
2018 Standout
Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1
2004
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease
2019 Standout
Apoptosis and angiogenesis: an evolving mechanism for fibrosis
2013
Multidrug Transporter ABCG2 Prevents Tumor Cell Death Induced by the Epidermal Growth Factor Receptor Inhibitor Iressa (ZD1839, Gefitinib)
2005
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
2011
Specific EGFR Mutations Predict Treatment Outcome of Stage IIIB/IV Patients With Chemotherapy-Naive Non–Small-Cell Lung Cancer Receiving First-Line Gefitinib Monotherapy
2008
Mutations of the Epidermal Growth Factor Receptor Gene Predict Prolonged Survival After Gefitinib Treatment in Patients With Non–Small-Cell Lung Cancer With Postoperative Recurrence
2005
Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19
2020 Standout
Molecular Predictors of Response to Epidermal Growth Factor Receptor Antagonists in Non–Small-Cell Lung Cancer
2007
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
2019 Standout
Fibrosis — A Common Pathway to Organ Injury and Failure
2015 Standout
First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring SomaticEGFRMutations
2008
Cancer Genome Landscapes
2013 StandoutScience
Endothelial Hypoxia-Inducible Factor-2α Is Required for the Maintenance of Airway Microvasculature
2019 StandoutNobel
Noninvasive Detection of EGFR T790M in Gefitinib or Erlotinib Resistant Non–Small Cell Lung Cancer
2009
Preterm labor: One syndrome, many causes
2014 StandoutScience
Neuroendocrine Mechanisms in Pregnancy and Parturition
2010
Predictors of the Response to Gefitinib in Refractory Non–Small Cell Lung Cancer
2005
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
2004 Standout
Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer
2008
Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2
2004
Works of Yuichiro Kimura being referenced
Expression of Urocortin and Corticotropin-Releasing Factor Receptor Subtypes in the Human Heart
2002
Severe acute interstitial pneumonia and gefitinib
2003
Heterogeneous Increase in CD34-positive Alveolar Capillaries in Idiopathic Pulmonary Fibrosis
2004
Prospective Phase II Study of Gefitinib for Chemotherapy-Naïve Patients With Advanced Non–Small-Cell Lung Cancer With Epidermal Growth Factor Receptor Gene Mutations
2006
Acute-onset Sarcoidosis with Erythema Nodosum and Polyarthralgia (Loefgren's Syndrome) in Japan: a Case Report and a Review of the Literature
2006